mk-8776
Small moleculeexperimental
Clinical trial activity
3 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Oct 1, 2008 (NCT00779584)
Timeline
Indications
Mechanism of action
- Serine/threonine-protein kinase Chk1INHIBITOR
CHEK1 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
Cn1cc(-c2cnn3c(N)c(Br)c([C@@H]4CCCNC4)nc23)cn1- Mol. weight
- 376.26 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2386889 ↗
Also known as
- mk8776
- mk-8776
- mk-8776
- mk-8776
- mk-8776
- mk-8776
- sch900776
- sch 900776
- sch 900776
- sch 900776
- sch-900776
- sch-900776
- sch-900776
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01870596 | Phase 2 | May 1, 2013 | Johns Hopkins University, National Cancer Institute (NCI) |
| NCT00907517 | Phase 1 | Jul 1, 2009 | Merck |
| NCT00779584 | Phase 1 | Oct 1, 2008 | Merck |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Merck | For profit | 2 | 2 | 1 | 2008 |
| Johns Hopkins University | Academic/Hospital | 1 | 0 | 1 | 2013 |
| National Cancer Institute (NCI) | Government | 1 | 1 | 1 | 2013 |
3 organizations
Page 1 / 1